Companies That Will Win the GLP-1 Economy

Eli Lilly paired the leading injectable rival to Wegovy with an oral GLP-1 program and huge manufacturing investment. More formats can expand an already large market.

Amgen is testing an obesity medicine designed for less frequent dosing. A monthly or quarterly schedule would matter if efficacy and tolerability remain competitive.

Hims & Hers already knows how to acquire patients, manage recurring prescriptions and deliver telehealth. That consumer relationship becomes valuable when drug supply broadens.

Ro combines prescribing, pharmacy coordination and ongoing patient support in one service. Those practical steps matter once the medicine itself stops being scarce.

Walmart can put lower-cost obesity treatment near millions of shoppers through pharmacies and clinics. Its scale matters more as access moves beyond specialist care.

CVS connects pharmacies, insurance benefits and regular patient contact. That reach gives it influence over both access and the economics of long-term treatment.

Novo Nordisk created the modern obesity-drug category and still owns deep clinical evidence, manufacturing expertise and physician trust. Losing momentum does not erase that base.

Viking produced strong weight-loss data from injectable and oral candidates. The pipeline makes it a credible partner or acquisition target rather than another early-stage promise.

Roche bought multiple obesity programs rather than depending on one molecule. That portfolio gives it several chances to find a useful combination or dosing advantage.

Zealand specializes in peptide medicines and has obesity candidates that could preserve lean mass or complement existing treatments. Partnership value may arrive before a consumer brand.